Thrombolex develops a differentiated pharmacomechanical lysis platform and markets FDA-cleared Bashir endovascular catheter systems designed to enable rapid thrombus reduction by integrating mechanical clot engagement with targeted thrombolytic delivery. The company is a commercial-stage device developer focused on pulmonary embolism and other thromboembolic diseases. Thrombolex is expanding its U.S. commercial infrastructure and advancing the generation of clinical evidence across its catheter platform. Financially, the company recently closed a $50 million Series A equity financing led by OrbiMed and supported by existing investors and cofounders to support those efforts. As part of the financing, Thrombolex added Keegan Harper as Executive Chairman and added board members including Sam Liang, David Bonita, and Clay DeMarcus.

Total raised

$50M

Funding rounds

1

Latest round

Series A

Latest activity

Mar 2026